Search Results
Mar 19, 2026, 10:00 ET Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
resistant to immunotherapy into viable targets. Institutions are positioning for this shift through companies like Oncolytics Biotech (NASDAQ: ONCY), Gilead Sciences (NASDAQ: GILD), enGene Holdings (NASDAQ: ENGN), TScan Therapeutics (NASDAQ: TCRX), and Day One Biopharmaceuticals
More news about: USA News Group
Mar 05, 2026, 09:00 ET Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
populations[2]. Companies delivering next-generation oncology treatments across multiple tumor types include Oncolytics Biotech (NASDAQ: ONCY), Vir Biotechnology (NASDAQ: VIR), Iovance Biotherapeutics (NASDAQ: IOVA), C4 Therapeutics (NASDAQ: CCCC), and Immunocore
More news about: Equity Insider
Mar 03, 2026, 09:00 ET Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
therapies[2]. Companies advancing breakthrough oncology pipelines across multiple indications include Oncolytics Biotech (NASDAQ: ONCY), Eli Lilly (NYSE: LLY), Gilead Sciences (NASDAQ: GILD), Arcellx (NASDAQ: ACLX), and Merck (NYSE: MRK).
More news about: USA News Group
Feb 25, 2026, 09:00 ET Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
therapy, and cancer vaccines[1]. Five companies positioned at the forefront of this expansion include Oncolytics Biotech (NASDAQ: ONCY), ImmunityBio (NASDAQ: IBRX), CRISPR Therapeutics (NASDAQ: CRSP), BioNTech (NASDAQ: BNTX), and Novocure (NASDAQ: NVCR).
More news about: Equity Insider
Feb 24, 2026, 10:58 ET Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
and immunotherapy adoption[2]. Five companies advancing novel approaches in the oncology sector include Oncolytics Biotech (NASDAQ: ONCY), Exelixis (NASDAQ: EXEL), Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), and Gilead Sciences (NASDAQ: GILD).
More news about: USA News Group
Feb 17, 2026, 11:25 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
platforms now generating survival data in tumor types that have resisted conventional approaches for decades. Oncolytics Biotech Inc. (NASDAQ: ONCY), Novocure (NASDAQ: NVCR), Perspective Therapeutics, Inc. (NYSE-A: CATX), ImmunityBio, Inc. (NASDAQ: IBRX), and Nuvation Bio
More news about: Equity Insider
Feb 17, 2026, 11:17 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
platforms now generating survival data in tumor types that have resisted conventional approaches for decades. Oncolytics Biotech Inc. (NASDAQ: ONCY), Novocure (NASDAQ: NVCR), Perspective Therapeutics, Inc. (NYSE-A: CATX), ImmunityBio, Inc. (NASDAQ: IBRX), and Nuvation Bio
More news about: Equity Insider
Feb 05, 2026, 09:35 ET $207B Market Shift: The Race for Fast Track Approval in Oncology
inhibitors and rare malignancies. This regulatory velocity creates a clear validation framework, positioning Oncolytics Biotech Inc. (NASDAQ: ONCY), Relay Therapeutics (NASDAQ: RLAY), MAIA Biotechnology (NYSE-A: MAIA), Zai Lab (NASDAQ: ZLAB), and Arrivent BioPharma (NASDAQ:
More news about: USA News Group
Jan 30, 2026, 10:36 ET $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
Phase 3 data and manufacturing infrastructure. This structural shift has directed institutional focus toward Oncolytics Biotech Inc. (NASDAQ: ONCY), AbbVie (NYSE: ABBV), Genmab (NASDAQ: GMAB), ADC Therapeutics (NYSE: ADCT), and Greenwich LifeSciences (NASDAQ: GLSI).
More news about: Equity Insider
Jan 30, 2026, 10:19 ET $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
immunologically "cold" GI tumors that have baffled researchers for decades. This regulatory tailwind places Oncolytics Biotech Inc. (NASDAQ: ONCY), Pfizer (NYSE: PFE), Verastem Oncology (NASDAQ: VSTM), Perspective Therapeutics (NYSE-A: CATX), and RenovoRx (NASDAQ: RNXT) directly
More news about: USA News Group
Jan 28, 2026, 09:15 ET Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
poised for rapid maturation as sector fundamentals strengthen. This structural shift creates a window for Oncolytics Biotech Inc. (NASDAQ: ONCY), BioNTech (NASDAQ: BNTX), MAIA Biotechnology (NYSE-A: MAIA), Acrivon Therapeutics (NASDAQ: ACRV), and ImmunityBio (NASDAQ:
More news about: USA News Group
Jan 27, 2026, 10:50 ET Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
response rates and durability[2]. This structural shift creates an asymmetric investment window for Oncolytics Biotech Inc. (NASDAQ: ONCY), Moderna (NASDAQ: MRNA), Merck (NYSE: MRK), Vir Biotechnology (NASDAQ: VIR), and Coherus Oncology (NASDAQ: CHRS) at the
More news about: Equity Insider
Jan 14, 2026, 10:52 ET Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
2030[2]. This high-stakes hunt for registration-ready assets is driving the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ: ONCY), Nurix Therapeutics (NASDAQ: NRIX), Erasca (NASDAQ: ERAS), Foghorn Therapeutics (NASDAQ: FHTX), and ORIC Pharmaceuticals (NASDAQ:
More news about: Equity Insider
Jan 12, 2026, 10:35 ET Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
2035[2]. This strategic pivot toward registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ: ONCY), CG Oncology (NASDAQ: CGON), Zentalis Pharmaceuticals (NASDAQ: ZNTL), ArriVent BioPharma (NASDAQ: AVBP), and PDS Biotechnology
More news about: USA News Group
Jan 07, 2026, 10:32 ET How $594B in Precision Tech is Cracking the Metastatic Cancer Code
back[2]. This fundamental shift toward "reprogramming" the body's defenses drives the investment case for Oncolytics Biotech Inc. (NASDAQ: ONCY), BriaCell Therapeutics Corp. (NASDAQ: BCTX) (TSX: BCT), Greenwich LifeSciences, Inc. (NASDAQ: GLSI), Citius Oncology (NASDAQ: CTOR),
More news about: USA News Group
Dec 31, 2025, 07:25 ET Smart Oncology: 5 Stocks Chasing the $317B Prize
protocols[2]. This convergence of diagnostic precision and therapeutic targeting defines the investment thesis for Oncolytics Biotech Inc. (NASDAQ: ONCY), Exact Sciences Corp. (NASDAQ: EXAS), Veracyte, Inc. (NASDAQ: VCYT), Hologic, Inc. (NASDAQ: HOLX), and Personalis, Inc. (NASDAQ:
More news about: USA News Group
Dec 16, 2025, 13:17 ET Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
immunologically cold tumors into treatment-responsive hot targets[2]. This pivotal shift positions Oncolytics Biotech Inc. (NASDAQ: ONCY), AIM ImmunoTech (NYSE-American: AIM), ArriVent BioPharma, Inc. (NASDAQ: AVBP), Merus N.V. (NASDAQ: MRUS), and Halozyme Therapeutics,
More news about: USA News Group
Dec 12, 2025, 10:47 ET Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
cancer models while maintaining potency in harsh tumor environments[2]. These advances position Oncolytics Biotech Inc. (NASDAQ: ONCY), Immuneering Corporation (NASDAQ: IMRX), Tango Therapeutics, Inc. (NASDAQ: TNGX), Moderna, Inc. (NASDAQ: MRNA), and Royalty
More news about: USA News Group
Oct 28, 2025, 07:30 ET Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care
SAN DIEGO, Calif., Oct. 28, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced updated results from the single-arm squamous
More news about: Oncolytics Biotech® Inc.
Oct 20, 2025, 09:00 ET Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed a registration
More news about: Oncolytics Biotech® Inc.
Sep 29, 2025, 08:30 ET Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
SAN DIEGO, Sept. 29, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced an update on the proposed design of its
More news about: Oncolytics Biotech® Inc.
Sep 16, 2025, 12:29 ET Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
tumor elimination in clinical trials across multiple cancer types[2]. These developments position Oncolytics Biotech Inc. (NASDAQ: ONCY), Anixa Biosciences, Inc. (NASDAQ: ANIX), IceCure Medical Ltd. (NASDAQ: ICCM), ImmunityBio, Inc. (NASDAQ: IBRX), and Regeneron
More news about: USA News Group
Sep 16, 2025, 07:00 ET Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
DIEGO, Sept. 16, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced updates on enrollment progress, U.S.
More news about: Oncolytics Biotech® Inc.